biotech
biotech Articles
Is it possible that analysts are now behind the curve on Alkermes? Or worse, are they chasing their expectations too high?
Published:
Last Updated:
Earnings season is now in full swing, and we have put together a preview of Bristol-Myers, AbbVie and some of the other top players in the health care sector.
Published:
Last Updated:
Americans generally would like to spend less money on health care. One way that this can be and will be accomplished is through the continued use and expanded use of generic drugs.
Published:
Last Updated:
These top biotech companies have been absolutely hammered and now trade at a valuation much lower than large cap pharmaceuticals.
Published:
Last Updated:
Puma Biotechnology, Inc. (NYSE: PBYI) recently filed with the U.S. Securities and Exchange Commission (SEC) for a secondary offering. No pricing details were announced, except that the offering would...
Published:
Last Updated:
Nektar Therapeutics plans to price 13 million shares at $13.50 for a secondary offering valued up to almost $202 million.
Published:
Last Updated:
Depomed has settled with Starboard Value in a move that will bring this activist investor fight to a close. At least for now.
Published:
Last Updated:
A new research report from Jefferies notes that when price momentum has been as bad as it has been recently, it tends to rebound in a big way.
Published:
Last Updated:
Myovant Sciences expects to price its 13 million shares in the range of $12 to $15 per share for an initial public offering valued up to more than $224 million.
Published:
Last Updated:
PTC Therapeutics shares took a dive early on Monday after the company announced a key FDA decision that wasn’t good.
Published:
Last Updated:
Myovant Sciences has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
Ocular Therapeutix and Regeneron are attempting to develop a sustained release formulation of aflibercept that is suitable for advancement into clinical development.
Published:
Last Updated:
Jefferies highlights top growth stocks to buy each week, and this week is no exception. These four all make good sense now and have outstanding upside potential.
Published:
Last Updated:
If a single failed clinical trial can mean disaster for a biotech stock, then short sellers can argue for a stock implosion down the road.
Published:
Last Updated:
KemPharm shares saw a solid gain on Tuesday following a key FDA approval on it treatment for attention deficit hyperactivity disorder.
Published:
Last Updated: